-- Earnings Flash (ABIO) ARCA BIOPHARMA Reports Q3 Loss $-0.33
4:21PM ET 11/02/2021 MT Newswires...
Quotes Snapshot > ABIO
ARCA Biopharma Inc ABIO:NASDAQ
Last Price$2.25NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.26 (6)
Ask (Size)$2.26 (1)
Day Low / HighN/A - N/A
Volume611.5 K
Read more news Recent News
Sector Update: Health Care Stocks Muted in Lead Up to Friday's Opening Bell
9:02AM ET 10/29/2021 MT NewswiresHealth care stocks were muted ahead of the opening bell on Friday. The Health Care SPDR (XLV) was flat while the iShares NASDAQ Biotechnology Index (IBB)...
Sector Update: Health Care
8:22AM ET 10/29/2021 MT NewswiresHealth care stocks inched lower ahead of the opening bell on Friday. The Health Care SPDR (XLV) was down 0.1% while the iShares NASDAQ Biotechnology Index...
ARCA biopharma Enrolls First International Patient in Phase 2b Trial of rNAPc2 to Treat COVID-19
9:14AM ET 9/16/2021 MT NewswiresARCA biopharma (ABIO) has enrolled the first international patient in a phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients...
View all Commentary and Analysis
Nuvo Group Begins U.S. IPO Effort
2:06PM ET 11/30/2021 Seeking AlphaU.S. IPO Weekly Recap: The Shortened Holiday Week Brings Just 1 IPO
10:43PM ET 11/27/2021 Seeking AlphaARCA biopharma (ABIO) Investor Presentation - Slideshow
1:41PM ET 8/23/2021 Seeking AlphaCompany Profile
Business DescriptionARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The firm focuses on the cardiovascular pathophysiology, molecular genetics, and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO. View company web site for more details
| Address | 10170 Church Ranch Way Westminster, Colorado 80021 |
| Phone | +1.720.940.2200 |
| Number of Employees | 15 |
| Recent SEC Filing | 12/02/2021 8-K |
| President, Chief Executive Officer & Director | Michael R. Bristow |
| Chief Operating Officer | Thomas A. Keuer |
| Chief Financial Officer | C. Jeffrey Dekker |
| Chief Medical Officer | Debra Marshall |
Company Highlights
| Price Open | $2.28 |
| Previous Close | $2.25 |
| 52 Week Range | $2.17 - 5.50 |
| Market Capitalization | $32.4 M |
| Shares Outstanding | 14.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/17/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.53 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -32.61% |
Analyst Ratings as of 11/11/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |